2025年4月6日 周日
Home > Archive>Volume 31, Issue 8, 2023 >711-719
PDF HTML XML Export Cite reminder
Research progress on the relationship between gut microbiota and cardiovascular diseases and the regulation of traditional Chinese medicine
CSTR:
[cstr]
Author:
Affiliation:

1.The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, ;2.Affiliated Hospital of Shandong University of Traditional Chinese Medicine, ;3.School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China)

Clc Number:

R5；R28

  • Article
    • | |
  • Metrics
    • |
  • Reference [73]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    With the development of population aging and urbanization, the morbidity and mortality of cardiovascular diseases are continuously increasing, posing a serious threat to human life, health and safety. The onset and course of cardiovascular diseases are affected by many factors, and the dysregulation of intestinal flora as one of them has attracted a lot of attention. Intestinal flora is a microflora that exists in the gastrointestinal tract and has a mutually-beneficial symbiosis with the human body. More and more studies have shown that the intestinal flora and cardiovascular diseases interact with each other, and the two are mutually causal, targeted intervention of cardiovascular diseases by regulating intestinal flora can become a new therapeutic idea. Modern studies have found that traditional Chinese medicine (TCM) compounds, TCM monomers and acupuncture can effectively correct the dysregulation of intestinal flora, up-regulate the number of probiotics, restore intestinal barrier function and reduce inflammation. Based on the above studies, this paper summarized the interaction between intestinal flora and its metabolites and cardiovascular diseases, and also summarized the therapeutic effects of some TCM in regulating intestinal flora, restoring the dynamic balance of intestinal flora, treating the heart with intestines and intervening in cardiovascular diseases, in order to provide new ideas and feasible schemes for the prevention and treatment of cardiovascular diseases.

    Reference
    [1] ROTH G A, MENSAH G A, JOHNSON C O, et al.Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 study.J Am Coll Cardiol, 0,6(25):2982-3021.
    [2] 胡盛寿, 高润霖, 刘力生, 等.《中国心血管病报告2018》概要.中国循环杂志, 9,4(3):209-220.HU S S, GAO R L, LIU L S, et al.Summary of China cardiovascular disease report 2018 .Chin Circ J, 9,4(3):209-220.
    [3] STRANDWITZ P.Neurotransmitter modulation by the gut microbiota.Brain Res, 8,3(Pt B):128-133.
    [4] PATTERSON E, RYAN P M, CRYAN J F, et al.Gut microbiota, obesity and diabetes.Postgrad Med J, 6,2(1087):286-300.
    [5] 洪于兴, 宁美, 颜习武, 等.中医药干预肠道菌群防治高血压合并认知障碍的探讨.南京中医药大学学报, 1,7(1):140-144.HONG Y X, NING M, YAN X W, et al.Discussion on the prevention and treatment of hypertension with cognitive impairment by intervention of intestinal flora with traditional Chinese medicine.J Nanjing Univ Tradit Chin Med, 1,7(1):140-144.
    [6] 陈宁宁.肠道菌群及其代谢产物靶向治疗心力衰竭的研究进展.临床与病理杂志, 1,1(7):1679-1684.CHEN N N.Research progress in the treatment of heart failure by targeting intestinal flora and its metabolites.Int J Pathol Clin Med, 1,1(7):1679-1684.
    [7] ILLIANO P, BRAMBILLA R, PAROLINI C.The mutual interplay of gut microbiota, diet and human disease.FEBS J, 0,7(5):833-855.
    [8] MARTIN-GALLAUSIAUX C, MARINELLI L, BLOTTIRE H M, et al.SCFA:mechanisms and functional importance in the gut.Proc Nutr Soc, 1,0(1):37-49.
    [9] 罗宏扬, 周昕, 沈涛, 等.基于肠道菌群探讨“饮食自倍, 肠胃乃伤”在代谢性疾病发生中的作用.时珍国医国药, 2,3(2):425-428.LUO H Y, ZHOU X, SHEN T, et al.Discussion “irregular diet, gastrointestinal injury” role in the development of metabolic diseases based on intestinal flora.Lishizhen Med Mat Med Res, 2,3(2):425-428.
    [10] JIN M C, QIAN Z Y, YIN J Y, et al.The role of intestinal microbiota in cardiovascular disease.J Cell Mol Med, 9,3(4):2343-2350.
    [11] QIN J J, LI R Q, RAES J, et al.A human gut microbial gene catalogue established by metagenomic sequencing.Nature, 0,4(7285):59-65.
    [12] 许杰, 王伊龙, 王拥军.肠道菌群与高血压.中国卒中杂志, 7,2(2):175-178.XU J, WANG Y L, WANG Y J.Gut microbiome and hypertension.Chin J Stroke, 7,2(2):175-178.
    [13] 李昕, 曹晓婷, 师宇, 等.冠心病患者的肠道菌群结构与舌苔相关性研究.时珍国医国药, 2,3(1):151-154.LI X, CAO X T, SHI Y, et al.Correlation between intestinal flora structure and tongue coating in patients with coronary heart disease.Lishizhen Med Mat Med Res, 2,3(1):151-154.
    [14] CUI L, ZHAO T T, HU H B, et al.Association study of gut flora in coronary heart disease through high-throughput sequencing.Biomed Res Int, 7,7:3796359.
    [15] KELLY T N, BAZZANO L A, AJAMI N J, et al.Gut microbiome associates with lifetime cardiovascular disease risk profile among Bogalusa Heart Study participants.Circ Res, 6,9(8):956-964.
    [16] KOREN O, SPOR A, FELIN J, et al.Human oral, gut, and plaque microbiota in patients with atherosclerosis.Proc Natl Acad Sci U S A, 1,8(Suppl 1):4592-4598.
    [17] JIE Z Y, XIA H H, ZHONG S L, et al.The gut microbiome in atherosclerotic cardiovascular disease.Nat Commun, 7,8(1):845.
    [18] 苏广胜, 王少君, 庞文跃.肠道菌群代谢产物TMAO与冠状动脉粥样硬化性心脏病关系的研究进展.山东医药, 0,0(34):104-107.SU G S, WANG S J, PANG W Y.Research progress on the relationship between intestinal flora metabolite TMAO and coronary atherosclerotic heart disease.Shandong Med J, 0,0(34):104-107.
    [19] WANG Z N, KLIPFELL E, BENNETT B J, et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.Nature, 1,2(7341):57-63.
    [20] TANG W H W, WANG Z N, LEVISON B S, et al.Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.N Engl J Med, 3,8(17):1575-1584.
    [21] 何卫斌, 段新杰, 王耀辉.肠道菌群代谢产物氧化三甲胺联合左室射血分数在慢性心力衰竭患者预后中的价值.中国循证心血管医学杂志, 1,3(4):443-446.HE W B, DUAN X J, WANG Y H.Prognostic value of trimethylamine oxide combined with left ventricular ejection fraction in patients with chronic heart failure.Chin J Evid-Base Cardiovasc Med, 1,3(4):443-446.
    [22] YUZEFPOLSKAYA M, BOHN B, NASIRI M, et al.Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant.J Heart Lung Transplant, 0,9(9):880-890.
    [23] NAGATOMO Y, TANG W H W.Intersections between microbiome and heart failure:revisiting the gut hypothesis.J Card Fail, 5,1(12):973-980.
    [24] DRAPALA A, SZUDZIK M, CHABOWSKI D, et al.Heart failure disturbs gut-blood barrier and increases plasma trimethylamine, a toxic bacterial metabolite.Int J Mol Sci, 0,1(17):6161.
    [25] WANG S C, ZHANG J Q, WANG Y L, et al.NLRP3 inflammasome as a novel therapeutic target for heart failure.Anatol J Cardiol, 2,6(1):15-22.
    [26] CUI X, YE L, LI J, et al.Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients.Sci Rep, 8,8(1):635.
    [27] ZHOU W Y, CHENG Y Y, ZHU P, et al.Implication of gut microbiota in cardiovascular diseases.Oxid Med Cell Longev, 0,0:5394096.
    [28] ZHANG R, MA W Q, FU M J, et al.Overview of bile acid signaling in the cardiovascular system.World J Clin Cases, 1,9(2):308-320.
    [29] MAYERHOFER C C K, UELAND T, BROCH K, et al.Increased secondary/primary bile acid ratio in chronic heart failure.J Card Fail, 7,3(9):666-671.
    [30] LI J, ZHAO F Q, WANG Y D, et al.Gut microbiota dysbiosis contributes to the development of hypertension.Microbiome, 7,5(1):14.
    [31] TORAL M, ROBLES-VERA I, DE LA VISITACIN N, et al.Critical role of the interaction gut microbiota-sympathetic nervous system in the regulation of blood pressure.Front Physiol, 9,0:231.
    [32] UFNAL M, JAZWIEC R, DADLEZ M, et al.Trimethylamine-N-oxide:a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin Ⅱ in rats.Can J Cardiol, 4,0(12):1700-1705.
    [33] CHEN H, LI J B, LI N, et al.Increased circulating trimethylamine N-oxide plays a contributory role in the development of endothelial dysfunction and hypertension in the RUPP rat model of preeclampsia.Hypertens Pregnancy, 9,8(2):96-104.
    [34] LIU M, HAN Q H, YANG J L.Trimethylamine-N-oxide (TMAO) increased aquaporin-2 expression in spontaneously hypertensive rats.Clin Exp Hypertens, 9,1(4):312-322.
    [35] MA J L, LI H K.The role of gut microbiota in atherosclerosis and hypertension.Front Pharmacol, 8,9:1082.
    [36] ZUBCEVIC J, RICHARDS E M, YANG T, et al.Impaired autonomic nervous system-microbiome circuit in hypertension.Circ Res, 9,5(1):104-116.
    [37] BARTOLOMAEUS H, BALOGH A, YAKOUB M, et al.Short-chain fatty acid propionate protects from hypertensive cardiovascular damage.Circulation, 9,9(11):1407-1421.
    [38] KAYE D M, SHIHATA W A, JAMA H A, et al.Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease.Circulation, 0,1(17):1393-1403.
    [39] XIAO L, DONG J H, TENG X, et al.Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling.J Hypertens, 8,6(3):651-665.
    [40] 林秋珍, 韩冰, 刘启明.心房颤动诊断管理指南更新解读.临床心血管病杂志, 1,7(5):485-488.LIN Q Z, HAN B, LIU Q M.Interpretation of the diagnosis and management of atrial fibrillation.J Clin Cardiol, 1,7(5):485-488.
    [41] ZUO K, LI J, LI K B, et al.Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation.Gigascience, 9,8(6):giz058.
    [42] ZHANG J, ZUO K, FANG C, et al.Altered synthesis of genes associated with short-chain fatty acids in the gut of patients with atrial fibrillation.BMC Genomics, 1,2(1):634.
    [43] YU L L, MENG G N, HUANG B, et al.A potential relationship between gut microbes and atrial fibrillation:trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation.Int J Cardiol, 8,5:92-98.
    [44] 赵鹏, 刘新新, 田进伟.肠道菌群代谢物与心血管疾病关系的研究进展.中国动脉硬化杂志, 1,9(12):1094-1098.ZHAO P, LIU X X, TIAN J W.Research progress in the relationship between intestinal flora metabolites and cardiovascular disease.Chin J Arterioscler, 1,9(12):1094-1098.
    [45] WANG X H, LI Z, ZANG M H, et al.Circulating primary bile acid is correlated with structural remodeling in atrial fibrillation.J Interv Card Electrophysiol, 0,7(3):371-377.
    [46] WANG M, XIONG H, LU L, et al.Serum lipopolysaccharide is associated with the recurrence of atrial fibrillation after radiofrequency ablation by increasing systemic inflammation and atrial fibrosis.Oxid Med Cell Longev, 2,2:2405972.
    [47] ZHANG Y, ZHANG S, LI B L, et al.Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome.Cardiovasc Res, 2,8(3):785-797.
    [48] 张占帅, 秦少强, 王亚玲, 等.急性心肌梗死患者血清人软骨糖蛋白39、可溶性肿瘤坏死因子受体1水平与心功能及预后的相关性.中国动脉硬化杂志, 2,0(3):243-247.ZHANG Z S, QIN S Q, WANG Y L, et al.Correlation between serum levels of human cartilage glycoprotein 39, soluble tumor necrosis factor receptor 1 and cardiac function, prognosis in patients with acute myocardial infarction.Chin J Arterioscler, 2,0(3):243-247.
    [49] ZHOU X, LI J, GUO J L, et al.Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction.Microbiome, 8,6(1):66.
    [50] 袁晓宇, 潘闵, 杨鹏, 等.血浆氧化三甲胺检测对急性心肌梗死患者心室重构及预后的评估价值.山东医药, 9,9(4):10-13.YUAN X Y, PAN M, YANG P, et al.Evaluation value of plasma trimethylamine oxide determination for ventricular remodeling and prognosis in patients with acute myocardial infarction.Shandong Med J, 9,9(4):10-13.
    [51] CARRERA-BASTOS P, PICAZO , FONTES-VILLALBA M, et al.Serum zonulin and endotoxin levels in exceptional longevity versus precocious myocardial infarction.Aging Dis, 8,9(2):317-321.
    [52] BOCCELLA N, PAOLILLO R, CORETTI L, et al.Transverse aortic constriction induces gut barrier alterations, microbiota remodeling and systemic inflammation.Sci Rep, 1,1(1):7404.
    [53] 谭展飞, 李浩, 马晓昌, 等.基于“心-肠”轴理论重塑肠道菌群干预动脉粥样硬化的研究.中药药理与临床, 1,7(6):174-177.TAN Z F, LI H, MA X C, et al.Research progress of intervention in atherosclerosis through gut flora based on “Heart-Gut” axis.Pharmacol Clin Chin Mat Med, 1,7(6):174-177.
    [54] 王雅琴, 张艳, 张伟, 等.从心-脾-肠轴理论探讨冠心病的诊疗.中医学报, 2,7(2):289-292.WANG Y Q, ZHANG Y, ZHANG W, et al.Discussion on diagnosis and treatment of coronary heart disease with theory of heart-spleen-gut axis.Chin J Chin Med, 2,7(2):289-292.
    [55] 陈维, 孟宪萌, 关乐, 等.大柴胡汤对冠心病不稳定型心绞痛血清Ghrelin和Obestatin的表达及肠道菌群构成的影响.中国实验方剂学杂志, 8,4(12):169-174.CHEN W, MENG X M, GUAN L, et al.Effect of Da Chaihutang on expression of serum Ghrelin and Obestatin and intestinal flora in unstable angina of coronary heart disease.Chin J Exp Tradit Med Form, 8,4(12):169-174.
    [56] 郭宗耀.基于“心与小肠相表里”探讨养心通脉方对冠心病血瘀证大鼠肠道菌群的影响.长沙:湖南中医药大学, 2017.GUO Z Y.Exploring the effect of Yangxin Tongmai dedoction on the intestinal microflora in rats of coronary heart disease with blood stasis syndrome based on the theory of “heart and small intestine share a paired relationship”.Changsha:Hunan University of Traditional Chinese Medicine, 2017.
    [57] 马晓聪, 熊兴江, 莫毅,等.基于16S rDNA测序技术的自发性高血压大鼠肠道菌群结构变化及中药干预作用.中华中医药学刊, 0,8(8):71-74.MA X C, XIONG X J, MO Y, et al.Study on changes of intestinal microflora in spontaneously hypertensive rats based on 16S rDNA sequencing and intervention of traditional Chinese medicine.Chin Arch Tradit Chin Med, 0,8(8):71-74.
    [58] 卢永康, 陈窕圆, 庄贤勉, 等.基于调节肠道菌群失衡的四君子汤干预心力衰竭大鼠机制研究.中国中医药信息杂志, 1,8(4):81-87.LU Y K, CHEN T Y, ZHUANG X M, et al.Mechanism study of Sijunzi decoction on rats with heart failure through regulating the imbalance of intestinal flora.Chin J Inform Tradit Chin Med, 1,8(4):81-87.
    [59] ZHOU G F, JIANG Y H, MA D F, et al.Xiao-Qing-Long tang prevents cardiomyocyte hypertrophy, fibrosis, and the development of heart failure with preserved ejection faction in rats by modulating the composition of the gut microbiota.Biomed Res Int, 9,9:9637479.
    [60] YU X Y, ZHANG X D, JIN H, et al.Zhengganxifeng decoction affects gut microbiota and reduces blood pressure via renin-angiotensin system.Biol Pharm Bull, 9,2(9):1482-1490.
    [61] 李贵明, 李燕.人参皂苷药理作用研究现状.中国临床药理学杂志, 0,6(8):1024-1027.LI G M, LI Y.Current status of research on the pharmacological effects of ginsenosides.Chin J Clin Pharmacol, 0,6(8):1024-1027.
    [62] 孙艺凡, 张霞, 王晓艳, 等.长期服用人参提取物对大鼠肠道菌群结构的影响.中国中药杂志, 8,3(19):3927-3932.SUN Y F, ZHANG X, WANG X Y, et al.Effect of long-term intake of ginseng extracts on gut microbiota in rats.Chin J Chin Mat Med, 8,3(19):3927-3932.
    [63] YIN H, LIU Z, LI F, et al.Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular remodeling in a rat model of myocardial infarction.J Mol Med (Berl), 1,9(4):363-375.
    [64] BAI X, FU R, DUAN Z, et al.Ginsenoside Rk3 alleviates gut microbiota dysbiosis and colonic inflammation in antibiotic-treated mice.Food Res Int, 1,6:110465.
    [65] 蔡红蝶, 宿树兰, 郭建明, 等.丹参对糖尿病肾损伤大鼠肠道菌群多样性的影响.中国中药杂志, 1,6(2):426-435.CAI H D, SU S L, GUO J M, et al.Effect of salviae miltiorrhizae radix et rhizoma on diversity of intestinal flora in diabetic nephropathy rats.Chin J Chin Mat Med, 1,6(2):426-435.
    [66] 罗晓雅, 杨志宏.肠道菌群与心血管疾病相关性的研究进展.中国药理学通报, 8,4(8):1037-1041.LUO X Y, YANG Z H.Research progress on correlation between intestinal flora and cardiovascular diseases.Chin Pharmacol Bull, 8,4(8):1037-1041.
    [67] 马艳春, 胡建辉, 吴文轩, 等.黄芪化学成分及药理作用研究进展.中医药学报, 2,0(4):92-95.MA Y C, HU J H, WU W X, et al.Research progress on chemical constituents and pharmacological effects of radix astragali.Acta Chin Med Pharmacol, 2,0(4):92-95.
    [68] 田雨, 丁艳平, 邵宝平, 等.黄芪等药食同源类中药作为功能性食品与肠道菌群的相互作用.中国中药杂志, 0,5(11):2486-2492.TIAN Y, DING Y P, SHAO B P, et al.Interaction between homologous functional food astragali radix and intestinal flora.Chin J Chin Mat Med, 0,5(11):2486-2492.
    [69] 韩聪, 姜月华, 李伟, 等.基于16S rDNA测序技术探索黄芪-丹参药对干预自发性高血压大鼠肠道菌群的机制.中华中医药杂志, 9,4(5):2233-2237.HAN C, JIANG Y H, LI W, et al.Study on the mechanism of astragalus and salvia miltiorrhiza on intestinal flora of spontaneously hypertensive rats based on 16S rDNA sequencing technology.Chin J Tradit Chin Med Pharm, 9,4(5):2233-2237.
    [70] 王芮.基于肠道菌群研究电针预处理对动脉粥样硬化的预防作用.沈阳:辽宁中医药大学, 2018.WANG R.Study on the preventive effect of electro-acupuncture pretreatment on atherosclerosis based on intestinal flora.Shenyang:Liaoning University of Traditional Chinese Medicine, 2018.
    [71] 苗嘉芮, 王多.电针对高血压病前期大鼠Toll样受体4信号通路的影响.中华中医药杂志, 7,2(7):3256-3258.MIAO J R, WANG D.Effects of electro-acupuncture treatment on TLR4 signaling pathway in prehypertension rats.Chin J Tradit Chin Med Pharm, 7,2(7):3256-3258.
    [72] FENG W W, AO H, PENG C, et al.Gut microbiota, a new frontier to understand traditional Chinese medicines.Pharmacol Res, 9,2:176-191.
    [73] XU J, CHEN H B, LI S L.Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota.Med Res Rev, 7,7(5):1140-1185.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

SUN Xitong, CHEN Bo, ZHANG Jinlong, ZHANG Shiliang. Research progress on the relationship between gut microbiota and cardiovascular diseases and the regulation of traditional Chinese medicine[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2023,31(8):711-719.

Copy
Share
Article Metrics
  • Abstract:857
  • PDF: 998
  • HTML: 0
  • Cited by: 0
History
  • Received:November 22,2022
  • Revised:December 13,2022
  • Online: July 20,2023
Article QR Code

You are the 27972 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025